Skip to main contentSkip to navigationSkip to search

Press releases and news

2023

Camurus to enter Large Cap segment on Nasdaq Stockholm

Camurus announces completed enrollment in the Phase 3 SORENTO study of CAM2029 in patients with neuroendocrine tumors

Camurus’ Interim Report Third Quarter 2023

Camurus receives improved ESG risk rating by Sustainalytics

Camurus to present at Jefferies 2023 Healthcare Conference London

Camurus raises financial guidance for the full year 2023

Camurus’ Nomination Committee appointed for the Annual General Meeting 2024

Camurus establishes new, sustainable headquarters and laboratories in Science Village, Lund

Camurus announces US launch of Brixadi™ for the treatment of moderate to severe opioid use disorder by Braeburn

Change in number of shares and votes in Camurus

Exercise of Camurus’ subscription warrant program 2020/2023

Camurus’ Interim Report Second Quarter 2023

Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly

Camurus’ octreotide SC depot (CAM2029) achieves superior treatment response compared to placebo in Phase 3 acromegaly trial

Camurus accepted as participant of the United Nations Global Compact

Change in number of shares and votes in Camurus

Camurus to present at Jefferies 2023 Healthcare Conference New York

Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder

Resolutions at the annual general meeting 2023 in Camurus

Camurus’ Interim Report January-March 2023

Load more press releases

Subscribe

Get the latest news from Camurus

Subscribe to receive latest news from Camurus directly to your email. 

Information types

By subscribing to news from Camurus, you agree to our privacy policy.

Thank you. You will get an e-mail message to activate your subscription.